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INTRODUCTION 
 
Steroid-resistant  nephrotic  syndrome 
(SRNS) is a malfunction of the glomerular  
 
filter,  a  common  problem  in  paediatric 
nephrology  practice  which  tends  to 
progress  to  end-stage  renal  disease 
(ESRD).
[1-9]  SRNS-causing  genes  are 
expressed  in  a  specialized  cell  type,  the 
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glomerular  podocyte.
[10]  Approximately, 
33%  of  infantile  and  10%–28%  of  all 
childhood  SRNS  cases  are  caused  by 
single-gene  mutations  of  one  of  4  genes 
encoding  the  podocyte  proteins;  NPHS1, 
NPHS2, LAMB2, and WT1.
[11-16] However, 
there are more than 80% of SRNS cases 
with unknown molecular etiology.
[11,13]  
 
Coenzyme  Q10  (CoQ10)  is  a  type  of 
endogenous  ubiquinone,  found  in  human 
cells. It is mostly synthesized by a cascade 
pathway  in  the  inner  membrane  of  the 
mitochondria.
[17] A small proportion is taken 
by  diet.
[18]  It  has  an  important  role  in  the 
mitochondrial  electron-transport  chain, 
transfers electrons from complex I and II to 
complex III.
[19] 
 
Besides  its  major  role  in  mitochondrial 
electron  transport,  it  has  several  different 
functions  which  include  protection  of 
membrane  phospholipids  and  serum 
lipoproteins  from  lipid  peroxidation,  and 
role in endothelial and membrane functions 
by preventing the mitochondrial membrane 
proteins  from  reactive  oxygen  species 
leading to oxidative damage.
[20,21] 
 
Synthesis of CoQ10 is a complex pathway 
that  has  not  been  explained  exactly.  It 
involves  at  least  10  different  enzymes, 
isolated  from  various  genomes  and  is 
termed  from  COQ1  to  COQ10.
[22,23]  As 
shown  in  figure  1,  on  the  first  step,  from 
mevalonate  pathway;  geranylgeranyl 
diphosphate  is  produced  and  formstwo 
substances.  One  is  decaprenyl 
diphosphate;  the  other  is  para- 
hydroxybenzoate  (PHB),  derived  from 
tyrosine  or  phenylalanine.  PHB  goes  to 
prenylation  with  PHB-
polyprenyltransferase.  This  enzyme  is 
encoded  by  CoQ2.
[19] Following  this  step, 
multiple  reactions  (catalyze  condensation, 
methylation,  decarboxylation,  and 
hydroxylation)  take  place  to  form 
coenzyme  Q10.  CoQ  3-8  encodes  the 
enzymes  having  role  in  these  multiple 
reactions.
[24]  Due  to  the  fact  that, 
sequenced reactions involved in synthesis 
process,  an  obligatory  need  of  enzymes 
and  regulatory  proteins  in  all  steps  is 
unleavable.  Any  dysfunction  of  regulatory 
proteins  and/or  enzymes  or  pathogenic 
mutations  of  encoding  genes  affect  the 
biosynthesis of CoQ10.
[25] Primary CoQ10 
deficiency  is  an  autosomal  recessive 
disorder.
[26]  Five  major  phenotypes  have 
been  described.  In  almost  all  types, 
findings of central nervous system, skeletal 
muscle  and  peripheral  nerve  involvement 
are seen.
[23,27-31] 
 
Oral  supplementation  with  CoQ10  has 
been  shown  to  improve  clinical 
symptoms.
[32-34] Thus early diagnosis has a 
crucial  role  in  follow-up.  Here,  we 
described  quinone-responsive six patients 
having CoQ2 mutations and presented with 
steroid-resistant NS. 
 
METHODOLOGY 
 
This  is  a  case  series.  Six  children  with 
steroid  resistant  nephrotic  syndrome 
followed  in  Ege  University  Paediatric 
Nephrology  Department,  having  no 
mutation detected in NPHS1, NPHS2 and 
WT1 genes; evaluated for CoQ2 mutation 
and  found  as  having  a  homozygous 
mutation on CoQ2 in the Molecular Genetic 
Research  Laboratory  of  Ege  University 
Medical  Faculty,  were  reviewed.  The 
presence  of  homozygous  mutation  on 
CoQ2  led  us  to  give  them  oral  CoQ10 
(quinone)  treatment.  We  summarised  the 
clinical and diagnostic features of these six 
cases  by  reporting  the  outcome  after  
CoQ10  supplement,  in  the  light  of  
literature review. The study was approved 
by Ethical Committee of the institution, and 
informed consent was obtained from each 
patient or patient’s relative. 
 
CASES 
 
CASE 1 
He  was  20  months  old,  delivered  after  a 
healthy  pregnancy  of  unconsangious 
marriage.  He  had  a  10  years  old  brother 
without any disease. Parents were healthy; 
his  uncle  (brother  of  mother)  was 
transplanted  for  chronic  renal  failure  with 
unknown etiology at the age of 16. At 14 
months  of  age,  he  was  admitted  to  our 
clinic  with  the  findings  of  nephrotic 
syndrome and acute renal failure. Serology 
for  hepatitis  B  and  C,  HIV,  Epstein-Barr 
virus,  and  parvovirus  B19  was  negative. 
Acute  treatment  was  begun,  but  rapidly 
progressed to end stage renal disease (on 
the second months of disease onset). The 
renal pathology revealed sclerosis in 33% 
of  glomerules,  global  sclerosis  in  25%  of 
glomerules  and  interstitial  fibrosis,  tubuler 
atrophy.  He  began  haemodialysis  after 
unsuccesful  peritoneal  dialysis  attempts. 
There  were  no  signs  of  neuromuscular 
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Table 1:  Features of  five different forms 
Form                  Component          References 
Encephalomyopathic Form    Exercise intolerance 
  Mitochondrial myopathy  
  Seizure 
  Cognitive impairment 
  Cerebellar symptoms 
       30,33,42,43 
 
InfantileEncephalopathic 
Form 
  Encephalopathy 
(hypotonia,  seizures, 
stroke-like  episodes, 
cerebellar and cerebral 
atrophy) 
  Optic nerve atrophy 
  Retinitis pigmentosa 
  Bilateral 
sensorineuronal 
deafness 
  Nephrotic  syndrome 
progression  to  renal 
failure  
  Renal tubulopathy 
  Progressive ataxia 
  Cardiomyopathy 
(ventricular 
hypertrophy) 
  Metabolic  disturbances 
(hypothermia,  lactic 
acidosis) 
  Developmental delay 
        29,31,44,45 
 
Cerebellar Form    Epilepsy  (most 
common) 
  Cerebellarathrophy, 
ataxia 
  Pyramidal signs  
  Mental retardation 
  Myopathic weakness  
  Delayed  motor 
development 
  Hypogonadism  (only  in 
2 cases) 
No  ragged-red  fibers  and  lipid 
storage  myopathy  on  muscle 
biopsy 
        46-49 
     There are 21 patients      
     reported in literatüre,     
     the most common form 
 
Leighsendrome    Growth retardation 
  Deafness 
  Ataxia 
        50 
Variant Isolated Myopathy    Exercise  intolerance 
(subacute onset) 
  Proximal  limb 
weakness 
Lipid  storage  and  ragged-red 
fibers in all muscle specimens,  
increased  serum  lactate  and 
creatine kinase 
        24,28 
        There are 4 patients      
        reported in literature 
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Figure  1:  CoQ10 biosynthetic  pathway.  Mevalonic  acid  pathway  generates  geranylgeranyl 
diphosphate.  Decaprenyl  diphosphate  is  synthesized  from  geranylgeranyl  diphosphate  by 
decaprenyl  diphosphate  synthase  enzyme.  Para-hydroxybenozoate  (PHB)  is  derived  from 
the  amino  acids  tyrosine  or  phenylalanine.  After  PHB  and  decaprenyl  diphosphate  are 
produced, at least seven enzymes catalyze condensation, methylation, decarboxylation, and 
hydroxylation reactions to synthesize CoQ 10.
[30,54,55] 
 
 
As  there  were  no  mutation  in  NPHS1, 
NPHS2 and WT1 genes, CoQ2 gene was 
examined  with  the  result  of  V66L 
homozygous  mutation.  There  was  V66L 
heterozygous  mutation  of  CoQ2  in  his 
mother, and no mutation  was detected in 
his father. Since then, the patient has been 
on  oral  supplementation  of  CoQ10  (30 
mg/kg per day). He has been on our follow 
up  with  a  well  functioning  graft  from  his 
mother  for 2 years. 
 
CASE 2 
An eight years old boy, having SRNS since 
he was 11 months. Pregnancy and delivery 
were not adversely eventful, and there was 
no  associated  family  history.  He  had 
moderate  motor-mental  retardation  and 
severe hearing loss. Mutations in NPHS1, 
NPHS2  and  WT1  genes  were  negative 
except  CoQ2  (V66L  homozygous).  His 
parents  had  no  mutation.  In  his  renal 
histology, there were 20% global sclerosis 
and  focal  fibrosis  in  interstitial  region, 
tubulary  athrophy.  After  CoQ10 
administration  for  a  year,  any  nephrotic 
syndrome  attacks  experienced  with  well 
renal functions. 
 
 
CASE 3 
The  patient  was  19  months  old  when  he 
had NS. NS was not responsive to steroid 
and cyclophosphamid therapy. On the third 
months of disease onset, ESRD was seen. 
He was born after a normal pregnancy with 
consangious marriage. He, his mother and 
father  had  heterozygous  mutation  about 
Canavan  disease.  He  had  a  brother  who 
died from Canavan disease at the age of 1 
year.  He  had  no  pathology  in  other 
systems  apart  from  kidneys.  He  went  for 
renal  biopsy  when  he  was  20months  of 
age.  Pathologic  findings  were  global 
sclerosis  in  more  than  half  glomerules, 
interstitial  fibrosis,  and  tubulary 
athrophy.While  NPHS1  and  NPHS2 
mutations revealed no mutation, CoQ2 had 
V66L  nucleotid  change.  He  is  on 
haemodialysis  programe  now,  preparing 
for  transplantation  with  administration  of 
CoQ10. 
 
CASE 4 
Patient was a 5-year old boy. He was born 
on the 27th weeks of pregnancy, and had 
NS  when  he  was  17  months  old.  There 
were  no  important  features  in  his  family 
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main pathologies. Almost in all glomerules 
(27  in  30)  global  sclerosis,  focal 
microcalcification,  fibrosis,  tubulary 
dilatation  were  noted  in  the  renal  biopsy. 
He responded to cyclosporin and CoQ10. 
 
CASE 5 
He was 13-years oldwith an infantile type 
of SRNS (age of onset: 12months). He had 
NS  attacks    more  than  5  times,  and  his  
attacks were resistant to cyclophoshamid. 
Renal  histology  was  evaluated  as  FSGS 
(more  than  half  glomerules  were  globally 
sclerotic).  Myopathy  was  the  only  sign  of 
neurologic  component  of  his  disease.  No 
mutation detected in NPHS1, NPHS2 and 
WT1  genes.  Homozygous  V66L  mutation 
was  found  in  CoQ2.  He  had  no  attacks 
after CoQ10 administration since 2 years.  
 
CASE 6 
This  was  an  8-year  old  girl  was  from 
unrelated  parents,  the  proband.  Disease 
onset  was  11  months;  with  histology 
suggestive of FSGS. She was responsive 
to  cyclosporin  treatment.  She  had  V66L 
heterozygous mutation on CoQ2. She was 
the  only  patient  that  presented  with 
isolated renal involvement. 
 
All  the  6  patients  were  responsive  to 
CoQ10 treatment. 
 
DISCUSSION 
 
Renal  dysfunction  associated  with 
mitochondriopathies  is  generally  a  rare 
event.
[35]  These  days,  number  of 
mitochondriopathies  presenting  with 
isolated renal involvement are increasing. 
This  study  reports  on  the  identification  of 
mutations  in  COQ2genes  ofubiquinone 
(CoQ10) synthesis pathway, in 6 unrelated 
patients.  The  genome  scan  analysis 
identified  mutation  in  the  COQ2(PDSS1) 
gene  encoding  prenyldiphosphate 
synthase, one of the key enzymes of the 
ubiquinone biosynthesis pathway.
[34,36] The 
absence of these mutation in control DNA 
samples of healthy children is a pointer to 
the pathogenicity.. 
 
There are few reported cases with CoQ 10 
deficiency  via  mutations  on  CoQ2  gene. 
Three  cases  that  presented  with  central- 
peripheral  nervous  system  involvement 
and nephrotic syndrome in the first decade 
of  life  were  previously  reported  in  the 
literature.
[34]  Ogasahara  et  al.  described 
first  patients  with  CoQ10  deficiency  in 
1989.
[37]  Two  sisters  developed  exercise 
intolerance,  slowly  developed  progressive 
weakness  of  axial  and  proximal  limb 
muscles,  myoglobinuria  and  brain 
involvement by learning disability.
[37] Exact 
diagnosis was reached by the assesment 
of  markedly  decreased  CoQ10 
concentrations  (about  5%  of  normal)  in 
muscle  biopsies.
[37]  In  a  study  done  by  
DiGiovanni et al. on patients with the same 
clinical  triad  (mitochondrial  myopathy, 
recurrent  myoglobinuria,  and  CNS  signs) 
and muscle CoQ10 deficiency appeared 8 
and 11 years later.
[33] Notably, all patients 
improved  remarkably  with  oral  CoQ10 
supplementation.  In  2000,  Rotig  et  al. 
described the first infantile-onset cases in 
three  siblings.
[34]  Soon  after  birth  with 
neurological  symptoms,  including 
nystagmus,  optic  atrophy,  sensorineural 
hearing  loss,  ataxia,  dystonia,  weakness, 
and rapidly progressive nephropathy were 
seen in all siblings in whom any causative 
mutations has been reported.
[34] 
 
Primary  CoQ10  deficiencies  have  been 
recognized  since  the  late  1980s,  but  no 
mutation  had  been  described  in  CoQ10 
synthesis  genes  until  the  first  decade  of 
21th
  century.
[22,30]  In  2006,  Quinzii  et  al. 
reported the first mutation responsible for 
CoQ10  deficiency  in  a  proband  with 
infantile-onset  multisystemic  disease  and 
his  younger  sister,  who  shared  a 
homozygous  missense  mutation  in  the 
CoQ2 gene.
[22] The elder sibling was a 33-
month-old  boy  having  nystagmus,  severe 
nephrotic  syndrome  and  psychomotor 
delay, at the age of 2, 12, and 18 months, 
respectively.
[22]  He  went  on  successful 
renal  transplant  at  3  years  of  age.  The 
sister developed nephrotic syndrome at 12 
months of age without any clinical signs of 
neurological  involvement.
[22]  Both  siblings 
improved  with  CoQ10  supplementation.
[22] 
Rotig  et  al.  reported  a  girl  with  neonatal 
neurological distress, nephrotic syndrome, 
hepatopathy,  pancytopenia,  diabetes, 
seizures, and lactic acidosis progressing to 
fatal multiorgan failure at  age  12 days.
[34] 
Rotig  et  al.  also  reported  quinone-
responsive  mitochondrial 
encephalomyopathy  in  two  siblings  with 
coenzyme  Q10  deficiency.
[34]  The  older 
brother also had anemia, liver failure, and 
renal insufficiency and died at the age of 1 
day.
[34]  Both  siblings  had  a  homozygous 
base-pair deletion in exon 7 of the CoQ2 
gene.
[34] Three patients among 4 reported 
by  Diomedi  et  al.  presented  with  isolated Dincel  et al.: CoQ10 supplementation in steroid-resistant nephrotic syndrome 
  Int J Med Biomed Res 2014;3(3):146-154 
151   
   
renal  symptoms.
[35]  Although  these  cases 
were diagnosed  as CoQ2 nephropathy, a 
group of mitochondrial cytopathy, they had 
isolated  renal  involvement,  without  any 
neuropathologic  findings.  Diomedi  et  al. 
called this entity as CoQ2 nephropathy.
[35] 
Similar  to  the  literature,  our  1st    and  6th 
patientshad only nephropathy, and the 5
th 
patient  had  only  myopathy  and 
physicomotor developmental retardation  6 
months  following  the  renal  findings.  This 
can be explained  by three reasons. First, 
ubiquitously expression of CoQ10 and high 
CoQ10  content  in  kidneys  can  be 
affected.
[38]  Second,  residual  enzyme 
activity may have prevented cell damage in 
other  organs.
[35]    Lastly,  enough  dietary 
intake  of  CoQ10  cured  the  impaired 
CoQ10 synthesis in some tissues. 
 
CoQ2  nephropathy  has  a  heterogeneous 
pattern  of  glomerular  lesions.
[35] Wharram 
et  al.  reported  that  podocyte  damage 
secondary  to  inherited  mitochondrial 
dysfunction  may  cause  visceral  cell 
depletion,  accumulation  of  extracellular 
matrix,  and  ultimately  sclerosis  of  the 
glomerular tuft.
[39] Findings documented by 
Lee et al. also support that of Wharrams’ 
study.  They  explain  that  mitochondrial 
diseases trigger epithelial cell proliferation 
(particularly  podocytes),  associated  with 
GBM  collapse.
[40]  FSGS  pathogenesis  is 
based  on  the  increased  apoptosis  of 
podocyte  cells  in  mitochondrial 
cytopathies.
[40]  The  result  that  injured 
podocytes  leads  to  proliferative  lesions  is 
stil unclear.
[40,41] 
 
An autoimmune response involves both the 
tubular interstitium and glomeruli, causing 
the  death  of  glomerular  podocytes  were 
demostrated  by  ultrastructural  analysis  in 
mitochondria of mutant mice.
[42,43] 
 
Our  biopsy  findings  included  mostly 
sclerotic  glomerules  and  tubulointerstisyel 
changes,  similar  to  literatue.  Also,  similar 
findings were reported in a murine model, 
in  which  animals  spontaneously  develop 
proteinuria  and  renal  disease  associated 
with the presence of numerous dysmorphic 
mitochondria  in  all  cell  types,  and 
histologically collapsing glomerulopathy.
[44] 
In  this  model,  a  mutation  in  the  gene 
encoding  for  a  mitochondrial  protein, 
involved in the CoQ10 synthesis pathway 
is  the  trigger  factor  of  mitochondrial 
dysfunction.
[41,44] 
 
Among  the  biopsy  findings,  presence  of 
extracapillary  proliferation  indicates  that 
there  was  pathology  also  in  parietal 
epithelial  cells  besides  to  podocytes.  All 
patients  responded  to  CoQ  10  treatment, 
similar  to  other  papers.
[1,35]  CoQ  10 
deficiency  is  strongly  related  with  CoQ2 
deficiency and/or any mutation of encoding 
genes.
[1,35] Among the 5 types of CoQ 10 
deficiency, infantile form can be presented 
only  with  renal  involvement,  nephrotic 
syndrome.
[45]  Also  in  other  forms,  renal 
involvement  is  not  rare  besides  the 
neurological pathologies.
[35] 
 
In conclusion, it is important to emphasize 
on  the  clinical  findings  of  CoQ10 
deficiency, related with CoQ2 nephropathy; 
as  it  can  only  begins  with  renal 
involvement, may cause the time wasting 
by  doing  molecular  analysis  of  other 
genes; such as NPHS1, NPHS2 anf WT1. 
It  should  be  put  in  mind  that  CoQ2 
nephropathy  and/or  CoQ10  deficiency 
should  be  on  the  top  list  of  differential 
diagnosis. This makes early recognition of 
CoQ2  nephropathy  possible.  CoQ10 
supplementation  improves  the  clinical 
symptoms  and  prevents  neurologic 
complications.  Long-term  follow-up  is 
important to define the prognosis of these 
patients. 
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